ReCode Therapeutics is a biopharmaceutical company developing precision medicines for genetic respiratory diseases with significant unmet medical need. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The Company's proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/28/20	$80,000,000	Series A	Colt Ventures Hunt Technology Ventures MPM Capital OrbiMed Advisors Osage University Partners Vida Ventures	undisclosed
09/19/23	$50,000,000	Series B	Amgen Ventures AyurMaya BLV EcoR1 Capital Leaps by Bayer MPM Capital OrbiMed Advisors Osage University Partners Pfizer Venture Investments Sanofi Ventures Solasta Ventures Vida Ventures	undisclosed
11/18/24	$15,000,000		Cystic Fibrosis Foundation	undisclosed